These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37282361)

  • 41. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
    Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers.
    Segal J; Esplen MJ; Toner B; Baedorf S; Narod S; Butler K
    Am J Med Genet A; 2004 Mar; 125A(3):267-72. PubMed ID: 14994235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening of BRCA1/2 variants in Mauritanian breast cancer patients.
    Brahim SM; Zein EE; Bonnet C; Hamed CT; Salame M; Zein MV; Khyatti M; Tolba A; Houmeida A
    BMC Cancer; 2022 Jul; 22(1):802. PubMed ID: 35858847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
    Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
    Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
    J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.
    Vos J; Oosterwijk JC; Gomez-Garcia E; Menko FH; Collee MJ; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
    Patient Educ Couns; 2012 Feb; 86(2):239-51. PubMed ID: 21684708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 53. Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants.
    Tercyak KP; Peshkin BN; Streisand R; Lerman C
    Psychooncology; 2001; 10(4):336-46. PubMed ID: 11462232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.
    Ingham SL; Warwick J; Byers H; Lalloo F; Newman WG; Evans DG
    Clin Genet; 2013 Jul; 84(1):37-42. PubMed ID: 23050611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
    Myklebust M; Gjengedal E; Strømsvik N
    J Genet Couns; 2016 Dec; 25(6):1198-1206. PubMed ID: 27091466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer worry among Norwegian male BRCA1/2 mutation carriers.
    Strømsvik N; Råheim M; Gjengedal E
    Fam Cancer; 2011 Sep; 10(3):597-603. PubMed ID: 21603983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their Relatives.
    Seven M; Shah LL; Daack-Hirsch S; Yazici H
    Cancer Nurs; 2021 May-Jun 01; 44(3):E142-E150. PubMed ID: 32022782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Germline
    Wiggins J; McLoughlin A; George A; Ring A; Kemp Z
    J Med Genet; 2020 Aug; 57(8):528-530. PubMed ID: 31511339
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.